ClearPoint Neuro: Q1 Earnings Insights
ClearPoint Neuro (NASDAQ:CLPT) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:05 PM. Here’s what…
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell
• Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter.
• Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.
ClearPoint Neuro Announces Agreement With NE Scientific To Integrate Gene Therapy Infusion Coverage Tool Into ClearPoint Maestro Brain Model
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive worldwide agreement with NE
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement With UCSF For Innovative Intra-Cerebral Cellular Delivery Platform
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
ClearPoint Neuro Announces First Patient Enrolled In Glioblastoma Trial Using ClearPoint Prism Neuro Laser Therapy System At Skåne University Hospital In Sweden
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced enrollment of the first patient in a Glioblastoma
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
ClearPoint Neuro Secures FDA Nod For ClearPoint Prism Neuro Laser Therapy System
ClearPoint Neuro Inc’s (NASDAQ:CLPT) Swedish partner, Clinical Laserthermia Systems (CLS), has received FDA 510(k) clearance for its laser, which the company…
Recap of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset…